Taiwan Stock Exchange · Healthcare
Visco Vision stock from India: price, numbers and tax
Visco Vision (6782) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Visco Vision at a glance
- Price
- NT$237.50-NT$4.50 (1.86%)
- Market cap
- NT$14.96B
- Day range
- NT$236.00 – NT$242.00
- P/E
- 14.39
- Dividend yield
- 3.54%
- Volume
- 242.10K
- 1 month
- -4.81%
- 6 months
- +20.25%
- YTD
- +36.10%
- 1 year
- +18.16%
- 5 years
- +89.24%
Visco Vision statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$4.2B | NT$3.7B | NT$2.4B | NT$2.8B | NT$2.0B |
| Gross profit | NT$1.9B | NT$1.4B | NT$857.2M | NT$1.2B | NT$839.3M |
| Operating income | NT$1.2B | NT$777.7M | NT$334.7M | NT$713.5M | NT$406.5M |
| Net income | NT$886.6M | NT$636.5M | NT$301.6M | NT$617.4M | NT$443.6M |
| Earnings per share | NT$14.08 | NT$10.10 | NT$4.79 | NT$11.11 | NT$8.11 |
| EBITDA | NT$1.7B | NT$1.2B | NT$733.6M | NT$1.1B | NT$667.5M |
| Total assets | NT$6.0B | NT$5.3B | NT$4.7B | NT$5.3B | NT$3.1B |
| Total debt | NT$481.9M | NT$844.3M | NT$1.1B | NT$1.4B | NT$1.2B |
| Cash and short-term investments | NT$795.7M | NT$805.3M | NT$720.8M | NT$1.8B | NT$351.0M |
| Shareholders' equity | NT$4.4B | NT$3.7B | NT$3.0B | NT$3.1B | NT$1.1B |
| Operating cash flow | NT$1.4B | NT$1.1B | NT$353.1M | NT$985.1M | NT$607.7M |
| Free cash flow | NT$829.3M | NT$605.5M | −NT$97.4M | NT$48.2M | −NT$304.0M |
| Capital expenditure | −NT$537.6M | −NT$510.3M | −NT$450.5M | −NT$936.9M | −NT$911.7M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Excelsior Medical | 4104.TW | NT$72.70 | NT$13.69B |
| Vizionfocus | 4771.TW | NT$213.50 | NT$12.53B |
| Foresee Pharmaceuticals | 6576.TWO | $79.10 | $12.46B |
| TaiDoc Technology | 4736.TW | NT$130.00 | NT$12.40B |
| TaiDoc Technology | 4736.TWO | $129.50 | $12.35B |
| Universal Vision Biotechnology | 3218.TWO | $134.00 | $11.35B |
| United Orthopedic | 4129.TWO | $82.60 | $7.97B |
| Bioteque | 4107.TWO | $110.50 | $7.66B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Visco Vision from India
What Visco Vision does
Visco Vision, Inc. engages in the production and sale of disposable soft contact lenses, It specializes in design and production of disposable contact lenses with different water content and oxygen permeability According to the same use cycle, it can be divided into daily, weekly, bi-weekly and monthly throws. The company offers general myopia correction, astigmatism, multifocal, anti-blue lens, and makeup lens that can change the color of the iris. Visco Vision operates in the Medical - Instruments & Supplies industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Visco Vision shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.